Effect of Cannabis Abuse and Ezymatic Alterations to Endorse Liver Dysfunctions

Irfan Ahmad Wani1*, Muzafar Ahmad Khan2 and Bhupinder Singh3

1Research Scholar Department of Psychology, Barkatullah University Bhopal, India
2Director Drug De-addiction and Rehabilitation Centre Police Control Room Srinagar Kashmir, India
3Professor Department of Psychology, Barkatullah University Bhopal, India

Submission: August 03, 2017; Published: August 16, 2017
*Corresponding author: Irfan Ahmad Wani, Research Scholar Department of Psychology, Barkatullah University Bhopal, Madya Pradesh, India, Tel; Email: wanizarar@gmail.com

Abstract

The present study is carried out to investigate the effect of cannabis abuse on liver functions by applying the liver function test to figure out the occurrence of enzymatic changes of the Cannabis Abusers and control group of Kashmir valley. The sample consisted of 250 (Liver function test) of male respondents; of these 125 were belong to cannabis abusers and 125 belong to control group were taken into consideration. The results of study showed that the two groups significantly differed on all the levels of liver function test (LFT). Cannabis abusers showed higher level of Total Bilirubin, Bilirubin direct, Bilirubin indirect, Aspartate amino transferase, Alinine amino transferase, Alkaline phosphate and Gamma glumutal transfersae and have showed lower levels of the protein total, Albumin, Glocublin and A:G ratio in comparison with control group.

Background: The menace of cannabis abuse has reached its peak in the Kashmir valley and is not only a socially unacceptable reality, but in its entirety is a disease and emerging as a major public health challenge not only in Kashmir region but throughout the globe.

Keywords: Cannabis abuse; Bilirubin; SGOT; SGPT; Albumin; Globulin & Gamma glumutal transfersae

Abbreviations: THC: Tetrahydrocannabinol; SMHS: Shri Maharaja Hari Singh High Streets; DDRC: Drug De-addiction and Rehabilitation Centre; PCR: Police Control Room

Introduction

The valley of Kashmir is geographically ideal for growing cannabis plants. It grows naturally on hills as well as plane regions in all the districts of the valley. Cannabis, one of the easy obtainable psycho-active drugs used by Kashmiri youth and is generally familiar by Charas, Tamooldh, Ater and Gardi in native languages. Kashmiri people are motivated and manipulated for its cultivation in their fields by its demand and price value in the international market somehow lack of vision and knowledge among drug peddlers squeezed the valley in hollowness. Cannabis addiction wore and spread among Kashmiri youth furiously that can’t control enough so far; which ruin school and college going students across the valley. It has been seen that the students mainly of the adolescence age bung their classes to extract the cannabis for intoxication. It has became a door step problem for parents to tackle and to protect their children from this alarming circumstance.

According to the data of Government Psychiatric Hospital Srinagar Kashmir India, the total numbers of drug addicts enrolled from January 2008 to May 2017 are 105,513 in which total number of inpatient are 38761 and the total number of outdoor patients are 66752. The psychiatric diagnosis applied on patients with the help of to ICD- classification revealed that the total no. of (F10 alcohol users 7365), (F11 opioid users 5252), (F12 cannabis users 22750), (F13 sedative users 13900), (F14 cocaine users 6513), (F15 stimulants users 10872), (F16 hallucinogens users 4522), (F17 nicotine users 1502), (F18 inhalant users 2044) and (F19 multiple drug users 30793). According to the data of Government Shri Maharaja Hari Singh High Streets Hospital Srinagar Kashmir (SMHS), the total numbers of drug addicts enrolled from January 2007 to May 2017 are 105773 in which total number of inpatient are 41241 and the total number of outdoor patients are 64532.
The psychiatric diagnosis applied on patients with the help of to ICD- classification revealed that the total no. of (F10 alcohol users 19729), (F11 opioid users 14688), (F12 cannabis users 25785), (F13 sedatives users 8712), (F14 cocaine 1630), (F15 stimulants are 1094), (F16 hallucinogens users 743), (F17 nicotine users 966), (F18 inhalant users 1464) and (F19 multiple drug users 30930). According to the data of Drug De-addiction and Rehabilitation Centre Police Control Room Srinagar Kashmir (DDRC, PCR), the total numbers of drug addicts enrolled from February 2014 to June 2017 are 16850 in which total number of inpatient are 1414 and the total number of outdoor patients are 16850. The psychiatric diagnosis applied on patients with the help of to ICD- classification revealed that the total no. of (F10 alcohol users 662), (F11 opioid users 1699), (F12 cannabis users 8245), (F13 sedatives users 1395), (F14 cocaine users 476), (F15 stimulant users 513), (F16 hallucinogen users 469), (F17 nicotine users 118), (F18 inhalant users 491) and (F19 multiple drug users 4226).

According to the data of Drug De-addiction and Rehabilitation Centre Baramulla Kashmir, the total numbers of drug addicts enrolled from January 2012 to June 2017 are 13406 in which total number of inpatient are 4784 and the total number of outdoor patients are 8622. The psychiatric diagnosis applied on patients with the help of to ICD- classification revealed that the total no. of (F10 alcohol users 1245), (F11 opioid users 1252), (F12 cannabis users 2524), (F13 sedatives users 1056), (F14 cocaine users 120), (F15 stimulants users 651), (F16 hallucinogens users 374), (F17 nicotine users 85), (F18 inhalants users 339) and (F19 multiple drug users 5760). According to the data of Drug De-addiction and Rehabilitation Centre District Islamabad Kashmir, the total numbers of drug addicts enrolled from 2012 to 2017 are 8332 in which total number of inpatient are 2802 and the total number of outdoor patients are 5450.

The psychiatric diagnosis applied on patients with the help of to ICD- classification revealed that the total no. of (F10 alcohol users 1089), (F11 opioid users 967), (F12 cannabis users 2087), (F13 sedatives users 648), (F14 cocaine users 140), (F15 stimulants users 324), (F16 hallucinogens users 280), (F17 nicotine users 90), (F18 inhalants users 144) and (F19 multiple drug users 2568). Data of concerning drug addiction and rehabilitation centers of the Kashmir valley postulates hypothesis that the cannabis is the first psychoactive drug after cigarette smoking used by youth and the average rate of cannabis intoxication is higher as compared to other drug use. The emerging consequence on physical health problems with cannabis abuse is far away from conscience of Kashmiri people so that the present study tries to estimate the drastic changes in some liver enzymes and figure out the effects of cannabis abuse on health due to enzymatic alteration which deliver the clinical importance twisted by the chronic cannabis abuse among humans.

**Literature Review**

Cannabis and its constituents have affected certain hepatic enzymes and causing a certain degree of liver dysfunction and liver were the major leakage sources of these enzymes [1]. The exotic effect of delta 9- tetrahydrocannabinol (THC) provoked preserve of certain liver enzymes used to digest the hepatic glycogen [2]. It was found that the activities of ALT and AST of cannabis users were significantly lower than the control group [3]. The natural cannabinoids such as O9-tetrahydrocannabinol (THC) have shown therapeutic potential in treating inflammatory diseases. Intraperitoneal administration of THC reserved hepatitis as shown by significant decrease in liver enzymes and reduced liver tissue injury.

Cannabinoids are possible hepatotoxic substances associated with hepatic morphologic and enzymatic alterations [4]. It also increase the (ALP) activity in both injected rats and human smokers and this will increase with the increase of dose and time but the (ALT) and the (AST) increase at the beginning of consumption then will decrease with time [5]. On the other hand it was seen that SGPT is more susceptible evaluating hepatocellular damage than SGOT [6]. Ironically, in patients with hepatitis C virus infection, daily cannabis use enlarged fibrosis succession instead of defensive patients against it [7]. It was also seen that in marijuana smokers, the mean GGT activity was 86.6% higher than that of the control group and that of alkaline phosphatase (ALP) was 121.7% higher than that of the non smokers group.

In addition, the total bile acids, which were synthesized from cholesterol in the liver, as well as the acetyl cholinesterase activity, were 39.2% higher and 11.3% lower than those of the corresponding control values, respectively. However the mean nitric oxide level was dramatically increased in sera of marijuana smokers (10.8%), the C-reactive protein level was only 40% higher in sera of marijuana smokers compared with those of the control group. Also, the mean SGPT activity was 19.4% and that of bilirubin level was 39.1% higher in sera of the smoker group than those of the healthy control group [8]. THC suppresses the production and induces the apoptosis of human hepatic myofibroblasts and stellate cells via CB2 receptors [9] and thus may be antifibrotic and hepatoprotective [10].

Cannabis addiction exaggerated the blood chemistry and affect neural functions mediated by these biogenic amines neurotransmission, while serotonin and 5HIAA levels were reduced and serum catecholamine levels were potentiated [11]. Endocannabinoids are lipid mediators of the same cannabinoid (CB) receptors that arbitrate the effects of marijuana. The endocannabinoid system (ECS) consists of CB receptors, endocannabinoids, and the enzymes implicated in their biosynthesis and degradation, and it is present in both...
brain and peripheral tissues, including the liver. The hepatic endocannabinoid system is activated in different liver diseases and contributes to the causal pathologies.

In patients with cirrhosis of various etiologies, the activation of vascular and cardiac CB1 receptors by macrophage-derived and platelet-derived endocannabinoids contribute to the vasodilated state and cardiomyopathy, which can be reversed by CB1 obstruction [12]. CB2 receptors are articolated mainly in immune and hematopoietic cells and detected in the liver in certain pathological states [7,9,10,13] Additional CB receptors may subsist but their prospective role in liver biology is unknown. Arachidonoyl ethanolamide also acknowledged as anandamide, was the first such ligand discovered [14] with 2-arachidonoyl glycerol (2-AG) identified 3 years later.

Supplementary endogenous ligand recognized such as arachidonoyl ethanolamide and 2-AG are generated on claim in response to swell in intracellular calcium or metabotropic receptor commencement [15]. Their biosynthesis from membrane phospholipids precursors may proceed along multiple parallel pathways [16,17]. Once released, they stay frequently membrane-associated because of their hydrophobic nature, and they can be taken up by cells via a high-affinity uptake mechanism [18]. This is followed by their enzymatic deprivation. Whereas 2-AG preferentially ruined by monoglyceride lipase [19].

While CB2 receptors are untraceable in the normal liver but are induced in pathological conditions such as nonalcoholic fatty liver disease [1], the embryonic state [20]. Liver fibrosis, [7,9,10] regenerating liver, [21] and hepatocellular carcinoma. Hepatic endocannabinoid levels are analogous to those in the brain, [22,23]. CB2 receptors, which are usually undetectable in the liver, are significantly expressed in the cirrhotic human liver and are also detectable in nonparenchymal liver cells in the fibrotic mouse liver [7,9]. The literature regarding many of its pharmacological and toxicological effects is unconvincing. This study will help to improvise the greater understanding of cannabis abuse and its penalty on liver functioning among humans and identifying gaps in the current literature.

**Aim**

The aim of the present study is to see the enzymatic alteration produced by cannabis abuse and to analyze the differences on liver function test (LFT) applied to a sample of 125 Cannabis Abusers and 125 from control group.

**Hypothesis**

There will be significant differences in Bilirubin total, Bilirubin direct, Bilirubin indirect, Aspartate amino transferase, Alanine amino transferase, Alkaline phosphate, Gamma glutamyl transferase, Albumin, Globulin, A:G RATIO (albumin-globulin ratio) levels between cannabis abusers and control group of kashmiri youth male.

**Methodology**

**Sample**

The sample consisted of 250 (LFT) tests of the male respondents. Of these, 125 were belong to cannabis Abusers remaining 125 were belong to control group. The mean age of the sample was 25.32 years. The Cannabis Abusers were selected from Drug De-addiction and Rehabilitation Center Police Control Room, Srinagar Kashmir, where as Non-abusers were randomly selected from Dahis clinical diagnostic labs Ganderbal Kashmir.

**Tool used**

Liver function test (LFT) is taken as a tool to analyze the enzymatic alteration produced by cannabis abuse (Table 1) (Figure 1).

Table 1: Depicts the mean SDs and t-values on (LFT) in cannabis abusers and control group of Kashmiri valley.

| Liver Function Test Serum | Methods | Biological Reference Range |
|---------------------------|---------|---------------------------|
| Bilirubin total           | Spectrophotometry, Diazo Method | 0.30-1.20 |
| Bilirubin direct          | Spectrophotometry, UV With Pyridoxal-5-Phosphate | 0.00-0.20 |
| Bilirubin indirect        | Spectrophotometry, PNP AMP Kinetic | 0.20-1.00 |
| Aspartate Amino Transferase (SGOT) | Spectrophotometry, G- Glutamyl-Carboxy-Nitroanalide | 15 – 37 |
| Alanine Amino Transferase (SGPT) | Spectrophotometry, Diazo Method | 16 – 63 |
| Alkaline Phosphate        | Spectrophotometry, Diazo Method | 46.0 - 116.0 |
| Gamma Glutamyl Transferase | Spectrophotometry, Bireet | 15 – 85 |
| Protein Total             | Spectrophotometry, Biuret | 6.4 - 82 |
| Albumin                   | Bromeresol Purple (BCP) | 3.4 - 5.0 |
| Gloublin                  | Bromeresol Purple (BCP) | 2.0 - 4.10 |
| A: G Ratio                | Bromeresol Purple (BCP) | 1.0 - 2.1 |
Result and Discussion

The t-test was applied to the obtained data to analyze the significance of a difference between the two groups, Cannabis Abusers and control group liver function test (Figure 1 and Table 1). The results showed the values of total Bilirubin, Bilirubin direct, Bilirubin indirect, Aspartate amino transferase, Alamine amino transferase, Alkaline phosphate and Gamma glutamyl transferase higher for the abusers group then those of the control group. Coherently, the level of the protein total, Albumin, Gloubulin and A: G ratio is lower for the abusers group then those of the control group. The “t” value on all the levels of (LFT) showed significant difference at (P<0.01).

Cannabis abusers showed higher scores in Total Bilirubin level of the Liver function test (M=14.78) in comparison of control group (M=11.1). In context of Bilirubin Direct level the cannabis abusers showed higher scores (M=9.14) in comparison of control group (M=5.07). In prospective of Bilirubin Indirect level the cannabis abusers showed higher scores (M=10.04) in comparison of control group (M= 7.83). Literature revealed that the Bilirubin is formed by the bustle of biliverdin reuctase on biliverdin, a green tetraptiryllic bile pigment that is also a product of heme catabolism. Bilirubin, when oxidized, reverts to become biliverdin once again and the potent antioxidant activity of bilirubin has led to the supposition that its main physiologic role is as a cellular antioxidant [24-26]. In the absence of liver disease, individuals with high levels of total bilirubin may experience various health benefits exceeding those with lower levels of bilirubin [27]. In other studies it was found that the higher levels of bilirubin in elderly individuals are associated with higher functional independence [28] but somehow the levels of serum bilirubin are inversely related to risk of certain heart diseases [2,29].
In the present study cannabis abusers showed higher scores in Aspartate amino transferase level (SGOT) (M=29.12) in contrast with control group (M=19.09) and in Alanine amino transferase level (SGPT) cannabis abusers showed higher scores (M=38.82) in relation with control group (M=22.01). A single dose of delta-9-THC succeeded in inhibiting hepatic microsomal enzymes but Serum glutamate oxaloacetate transaminase (SGOT) activity was amplified appreciably in adult male rats exposed to hashish smoke for 50 min, whereas serum glutamate pyruvate transaminase (SGPT) activity was impulsive. The enzymes are to be the more insightful determine for evaluating hepatocellular damage and showed severely improved activity in the plasma ALT and AST in rat groups [30-33].

In context of Alkaline phosphate level of liver function test cannabis abusers showed higher scores (M=75.72) in contrast with control group (M=51.6). Cannabis abusers showed higher scores in Gamma glutamyl transferase level (M=68.82) in comparison with control group (M=48.78). In addition, the serum gamma glutamyl transeptidase (GGTP), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) activities in 40 drug dependent patients. GGTP elevation was observed in 50% of drug estimate changes in some enzymes of clinical importance in rats exposed to cannabinoids and in men addicted to Cannabis smoking. Injection of rats with different doses of petroleum ether extract of Cannabis sativa resulted in a marked change in these plasma enzymes activities.

Alkaline phosphatase (ALP) activity was increased in rats with the increase of dose and time and the difference between the level in the high and the low dose groups was significant during and after the experimental period. Alanine aminotransferase (ALT) activity showed incredible increase after the second dose in the high dose group compared to the control group but returned to a lower level after the last dose, and Aspartate amino transferase (AST) activity revealed also significant elevation after the second dose, but after the last dose the activity decreased significantly compared to the control group. Adult addicted men smoked Cannabis for different periods showed slight numerical increase in (ALP) activity with the increase of the length of the period of Cannabis smoking. In contrast the activity of the (ALT) and the (AST) reported significantly lower levels compared to the non smokers group [34].

In context of Protein total level cannabis abusers showed lower scores (M=5.58) in comparison with control group (M=9.97). Cannabis abusers showed lower scores in Albumin level (M=2.44) in contrast with control group (M= 4.54). In perspective of Globulin level of liver function test the cannabis abusers showed lower scores (M=2.03) in relation with control group (M=4.98). In perspective of A: G Ratio level the cannabis abusers showed lower scores (M=3.44) in comparison with control group (M= 6.71). Literature revealed that the concentrations of serum albumin, total protein, electrolytes and glucose were not significantly tainted by marijuana addiction. Serum concentrations of serotonin and 5-hydroxy indole acetic acid (SHIAA) were extensively decreased although the serum levels of dopamine, noradrenaline and adrenaline were significantly increased.

The existence of precise cannabinoids (CB) receptors in mammalian tissues was first revealed by radioligand binding, and was followed by the molecular cloning of two G protein–coupled CB receptors [15]. CB1 receptors are mainly abundant receptors in the mammalian brain, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues, including various cell types of the liver, but expressed in peripheral tissues. Abnormal range in these enzymes leads to destruction of red blood cells, hepatitis or cirrhosis, gall stones or blockage of bile duct, weaker immune system bone problems like rickets, osteomalacia, cardiovascular disorder,kidney diseases, lung cancer and testicular cancer rarely seen among chronic abusers. They should endow psychological therapies such as motivational assessment therapy, spiritual therapy, yoga, meditation, group therapy, family and deviant behaviors of the addicted group.

The evident and potential health implications for CUD is at odds with its historical standing as a typically benign substance, and this has been significantly compounded by the current lack of effective and tailored treatment avenues [31]. No evidence based pharmacotherapies are currently available neither for the management of cannabis withdrawal and cravings, nor for complex presentations where comorbid drug abuse is evident. Rather, consultants and mental health professionals working in the field help the abusers by taking the various medical tests so that a clear picture comes out and diagnosis will be easily evolved however implementation of brief cognitive behavioural therapy and contingency management have indicated the strongest evidence for success [32]. The religious leaders and society committees should take serious measures against drug peddling and usage of psychoactive substances in the societies by taking the assistance of J&K police department and collaborative drug de-addiction and rehabilitative centers to put away the youth of the valley [35-42].

Religion is the way to be protective against the use of cannabis [33]. The government should deploy the police force to stop cannabis cultivation and other drug peddling or trafficking in the valley and take prolific steps in construction of new Drug De-Addiction and Rehabilitation Centers for both the genders and formulate strategies of making seminars, debates, rallies
References

1. Mendez-Sanchez N, Zamora-Valdes D, Pichardo-Bahena R, Barredo-Prieto B, Ponciano-Rodriguez G, et al. (2007) Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. Liver Int 27: 215-219.

2. Schwertner, Harvey A, Vitek, Libor (2008) "Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: Possible protective effects and therapeutic applications of bilirubin". Atherosclerosis 198 (1): 11-11.

3. Kew Alc, Bersohn I, Siew S (1969) Lancet (1): 578-579.

4. Borini P, Guimarães RC, Borini SB (2004) Possible hepatotoxicity of chronic marijuana usage Sao Paulo Med J 122(3): 110-116

5. Amma HM, Elbagir NY, Garbar AA, et al. (2011) The effect of cannabis sativa on certain enzymes of clinical significance in rats and men. Journal of pharmacognosy issn I(2): 10-13

6. Huy ND, Galkis L, Cote G, Roy PE (1975) Int J Clin Pharmacol. Biopharm 12 (1-2): 284-289.

7. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, et al. (2005) Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 42: 63-71.

8. Toson, El-Shahat A (2011) Impact of marijuana smoking on liver and sex hormones: Correlation with oxidative stress. Nature and Science 9(12): 76

9. Juliń B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, et al. (2005) Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 120: 742-755.

10. Lotersztajn S, Teixeira-Clerc F, Julien B, Deveaux V, Ichigotani Y, et al. (2008) CB2 receptors as new therapeutic targets for liver diseases. Br J Pharmacol 153: 286-289.

11. OAT Ebuehi, AI Akinwande, FO Fumuyiwa, EO Uzodimma, OA Adebayo, et al. (2005) Effect of Marijuana Smoking on Blood Chemistry and Serum Biogenic Amines Concentrations in Humans. Nigerian Journal of Health and Biomedical Sciences 4(1): 20-24.

12. Tam J, Liu J, Mukhopadhyay B, Ginar R, Godlewski G, et al. (2011) Endocannabinoids in Liver Disease. HEPATOLOGY 53(1): 346-355

13. Ashton JC, Rahman RM, Nair SM, Sutherland BA, Glass M, et al. (2007) Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci Lett 412: 114-117.

14. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949.

15. Pacher P, Batki S, Kunos G (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462.

16. Liu J, Wang L, Harvey-White J, Osei-Hyiaman D, Razdan R, et al. (2006) A biosynthetic pathway for anandamide. Proc Natl Acad Sci USA 103: 13345-13350.

17. Simon GM, Cravatt BF (2008) Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerocephospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem 283: 9341-9349.

18. Fowler CJ (2007) The pharmacology of the cannabinoid system: a question of efficacy and selectivity. Mol Neurobiol 36: 15-25.

19. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona L, et al. (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA,99: 10819-10824.

20. Buckley NE, Hansson S, Harte G, Mezey E (1998) Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat. Neuroscience 82: 1131-1149.

21. Teixeira-Clerc F, Bolot MP, Manin S, Deveaux V, Cadoulal T, et al. (2010) Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. HEPATOLOGY 52: 1046-1059.

22. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radova S, et al. (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115(5): 1298-1305.

23. Siegmund SV, Qian T, de Minicis S, Harvey-White J, Kunos G, et al. (2007) The endocannabinoid 2-arachidonoylglycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J 21: 2798-2806.

24. Baranano DE, Rao M, Ferris CD, Snyder SH (2002) “Biliverdin reductase: A major physiologic cytoprotectant”. Proceedings of the National Academy of Sciences 99 (25): 16093-16098

25. Sedlak TW, Saleh M, Higginson DS, Paul BD, Juluri KR, et al. (2009) “Bilirubin and glutathione have complementary antioxidant and cytoprotective roles”. Proceedings of the National Academy of Sciences 106 (13): 5171-5176.

26. Liu Y, Li P, Lu J, Xiong W, Oger J, et al. (2008) "Bilirubin possesses powerful immunomodulatory activity and suppresses experimental autoimmune encephalomyelitis". Journal of Immunology 181 (3): 1887-1897.

27. Sedlak TW, Snyder SH (2004) “Bilirubin Benefits: Cellular Protection by a Biliverdin Reductase Antioxidant Cycle”. Pediatrics 113 (6): 1776-1782.

28. Kao TW, Cho HS, Wang CC, Chou CH, Liu J, et al. (2012) “Associations between serum total bilirubin levels and functional dependence in the elderly”. Internal Medicine Journal 42 (11): 1199-1207.

29. Novotný L, Vitek L (2003) "Inverse relationship between serum bilirubin and atherosclerosis in men: A meta-analysis of published studies". Experimental Biology and Medicine 228 (5): 568-71.

30. Boutwell JH (1961) Iodine (protein bound). In: (2nd ed) ...Clinical Chemistry, Laboratory Manual and Methods . Lea and Febiger, Philadelphia, USA pp. 197.

31. Dennis M, Bahor TF, Roebuck MC, Donaldon J (2002) Changing the focus: the case for recognizing and treating cannabis use disorders. Addict 97: 4-15.

32. Copeland J, Swift W (2009) Cannabis use disorder: epidemiology and management. Int Rev Psychiatry 21: 96-103.

33. Gmel G, Mohler-Kuo M, Dermota P, Gaume J, Bertholet N, et al. (2013) Religion is good, belief is better: religion, religiosity, and substance use among young swiss men. Subst Use Misuse 48(12): 1085-1098.

34. Patel, Shanta, O’Gorman P (1975) J. clin. Path (28): 414-417.
35. Cheifetz, Adam S (2010) Oxford American Handbook of Gastroenterology and Hepatology. Oxford: Oxford University Press, USA. pp. 165.
36. Kuntz, Erwin (2008) Hepatology: Textbook and Atlas. Germany. p. 38
37. Lightner, David A (2013) Bilirubin: Jekyll and Hyde Pigment of Life. Springer.
38. Mahfouz M, Maker AB, Ghoneim MT, Mikhail HM (1975) Pharmazie (12): 772-774.
39. Moyer, Kathryn D, Balistreri, William F (2011) Liver Disease Associated with Systemic Disorders”. In Kliegman, Robert M, Stanton, Bonita F, St. Gme, Joseph W, Schor, Nina E, Behrman, Richard E, Nelson Textbook of Pediatrics. Saunders. pp. 1405.
40. Poddar MK, Ghosh J (1972) Biochemical Pharmacology 21(24): 3301-3303.
41. Stocker R, Yamamoto Y, McDonagh A, Glazer A, Ames B (1987) Bilirubin is an antioxidant of possible physiological importance. Science 235 (4792): 1043-1046.
42. Toson, El-Shahat A (2011) Impact of marijuana smoking on liver and sex hormones: Correlation with oxidative stress. Nature and Science 9(12): 76.

Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats (Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
https://juniperpublishers.com/online-submission.php

This work is licensed under Creative Commons Attribution 4.0 License
DOI: 10.19080/GJARM.2017.03.555605